Browsing by Author "Scorticati, C."

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Prognostic factors in de novo metastatic renal cell carcinoma: A report from the latin american renal cancer group
    (American Society of Clinical Oncology, 2021) Abreu, D.; Decia, R.; Carvalhal, G.; Gueglio, G.; Tobia, I.; Garcia, P.; Zuñiga, A.; Meza, L.; Bengio, R.; Scorticati, C.; Castillejos, R.; Rodriguez, F.; Autran, A.M.; Gonzales, C.; Gadu, J.; Nolazco, A.; Ameri, C.; Zampolli, H.; Langenhin, R.; Muguruza, D.; Machado, M.T.; Mingote, P.; Yandian, J.; Clavijo, J.; Nogueira, L.; Clark, O.; Secin, F.; Rovegno, A.; Vilas, A.; Barrios E.; Guimarães, G.; Zequi, S.C.; Glina, S.; Pal, S.K.; Rodriguez, O.; Palou, J.; Spiess, P.; Lara, P.N.; Marston Linehan, W.; Pastore, A.L.
    © 2021 by American Society of Clinical Oncology.PURPOSE To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries. PATIENTS AND METHODS Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 2015, a total of 530 (14.5%) had metastasis at clinical presentation. Relationships between clinical and pathological parameters and treatment-related outcomes were analyzed by Cox regression and the log-rank method. RESULTS Of 530 patients, 184 (90.6%) had died of renal cell carcinoma. The median OS of the entire cohort was 24 months. American Society of Anesthesiology classification 3-4 (hazard ratio [HR]: 1.64), perirenal fat invasion (HR: 2.02), and ≥ 2 metastatic organ sites (HR: 2.19) were independent prognostic factors for 5-year OS in multivariable analyses. We created a risk group stratification with these variables: no adverse risk factors (favorable group), median OS not reached; one adverse factor (intermediate group), median OS 33 months (HR: 2.04); and two or three adverse factors (poor risk group), median OS 14 months (HR: 3.58). CONCLUSION Our study defines novel prognostic factors that are relevant to a Latin American cohort. With external validation, these easily discerned clinical variables can be used to offer prognostic information across low- and middle-income countries.